- 著者
- Yuji Okuyama Takuya Ymaguchi Naoki Matsunaga Go Sakai
- 出版者
- The Japan Institute of Metals and Materials
- 雑誌
- MATERIALS TRANSACTIONS (ISSN:13459678)
- 巻号頁・発行日
- vol.59, no.1, pp.14-18, 2018-01-01 (Released:2017-12-25)
- 参考文献数
- 12
- 被引用文献数
- 1 6
In order to clarify the effect of the dopant concentration and phase transition on the proton conduction and proton concentration, the electrical conductivity and proton concentration were determined for La1−xBaxYb0.5In0.5O3−δ (x = 0.1. 0.3. 0.5, 0.7). The phase transition from the orthorhombic system to the cubic system was over x = 0.3. The proton/deuteron isotope effect on the conductivity was observed for all samples at 673 K. The proton concentration was independent of the barium content above 673 K. The proton concentration increased with the barium content below 673 K, but the concentration ratio of the proton to dopant decreased following an increase in the barium concentration. It was determined that the dopant concentration and phase transition do not have an influence on the conduction and incorporation of protons into the La1−xBaxYb0.5In0.5O3−δ.
- 著者
- Hiroshi Inoue Ken Okumura Hirotsugu Atarashi Takeshi Yamashita Hideki Origasa Naoko Kumagai Masayuki Sakurai Yuichiro Kawamura Isao Kubota Kazuo Matsumoto Yoshiaki Kaneko Satoshi Ogawa Yoshifusa Aizawa Masaomi Chinushi Itsuo Kodama Eiichi Watanabe Yukihiro Koretsune Yuji Okuyama Akihiko Shimizu Osamu Igawa Shigenobu Bando Masahiko Fukatani Tetsunori Saikawa Akiko Chishaki on behalf of the J-RHYTHM Registry Investigators
- 出版者
- 日本循環器学会
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-13-0290, (Released:2013-05-25)
- 参考文献数
- 24
- 被引用文献数
- 52 107
Background: Target anticoagulation levels for warfarin in Japanese patients with non-valvular atrial fibrillation (NVAF) are unclear. Methods and Results: Of 7,527 patients with NVAF, 1,002 did not receive warfarin (non-warfarin group), and the remaining patients receiving warfarin were divided into 5 groups based on their baseline international normalized ratio (INR) of prothrombin time (≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0). Patients were followed-up prospectively for 2 years. Primary endpoints were thromboembolic events (cerebral infarction, transient ischemic attack, and systemic embolism), and major hemorrhage requiring hospital admission. During the follow-up period, thromboembolic events occurred in 3.0% of non-warfarin group, but at lower frequencies in the warfarin groups (2.0, 1.3, 1.5, 0.6, and 1.8%/2 years for INR values of ≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0, respectively; P=0.0059). Major hemorrhage occurred more frequently in warfarin groups (1.5, 1.8, 2.4, 3.3, and 4.1% for INR values ≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0, respectively; P=0.0041) than in non-warfarin group (0.8%/2 years). These trends were maintained when the analyses were confined to patients aged ≥70 years. Conclusions: An INR of 1.6–2.6 is safe and effective at preventing thromboembolic events in patients with NVAF, particularly patients aged ≥70 years. An INR of 2.6–2.99 is also effective, but associated with a slightly increased risk in major hemorrhage. (UMIN Clinical Trials Registry UMIN000001569)